Abbott Reports the US FDA’s Approval of Alinity M High Risk (HR) HPV assay for the Detection of HPV Infections
Shots:
- The Alinity m high-risk HPV assay has been approved for use as a test for HPV identification and for regular cervical cancer screening. Additionally, it is also approved in combination with a Pap test (co-testing)
- The assay is significant because it provides data on 5 risk groups encompassing the 14 distinct virus genotypes that may cause cancer
- The test will be available through the Alinity m laboratory instrument. Additional assays are available for use in the US incl. SARS-CoV-2, Resp-4-Plex, HCV, HBV, HIV-1, STI (CT/NG/TV/MG), CMV & EBV
Ref: Abbott | Image: Abbott
Related News:- Abbott Reports Trial Results for Esprit BTK in Chronic Limb-Threatening Ischemia (CLTI)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
